Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT02741739
Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)
- Conditions
- Nonproliferative Diabetic Retinopathy
- Interventions
- Drug: ShamDrug: Intravitreal aflibercept injection [IAI]
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 402
- Registration Number
- NCT02718326
- Locations
- 🇺🇸
Regeneron study Site, Tucker, Georgia, United States
🇬🇧Regeneron Study Site, London, United Kingdom
🇺🇸Regeneron Study Ssites, Marietta, Georgia, United States
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Drug: Intravitreal Aflibercept Injection (IAI)
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 365
- Registration Number
- NCT02713204
- Locations
- 🇺🇸
Regeneron Investigational Site 3, Phoenix, Arizona, United States
🇺🇸Regeneron Investigational Site 1, Fort Worth, Texas, United States
🇺🇸Regeneron Investigational Site 2, Fort Worth, Texas, United States
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
- Conditions
- Diabetic Macular Edema
- Interventions
- Drug: Intravitreal Aflibercept Injection (IAI)
- First Posted Date
- 2016-03-17
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 302
- Registration Number
- NCT02712008
Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip
- Conditions
- Osteoarthritis of the Knee or Hip
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 5331
- Registration Number
- NCT02683239
- Locations
- 🇺🇸
Regeneron Investigational Site (4 locations), Phoenix, Arizona, United States
🇬🇧Regeneron Investigational Site, Sidcup, United Kingdom
🇺🇦Regeneron Investigational Site #1, Kyiv, Ukraine
Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy
- First Posted Date
- 2016-02-11
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 199
- Registration Number
- NCT02680184
- Locations
- 🇺🇸
Georgetown, Washington, District of Columbia, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies
- Conditions
- Relapsed/Refractory Aggressive B-Cell Lymphoma
- Interventions
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT02651662
- Locations
- 🇵🇱
Copernicus Memorial Hospital, Lodz, Poland
🇺🇸Harvard Medical School - Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸University of California Los Angeles Medical Center, Santa Monica, California, United States
Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2016-08-22
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT02647086
- Locations
- 🇺🇸
Regeneron Study Site, Raleigh, North Carolina, United States
A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain
- First Posted Date
- 2015-12-02
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 563
- Registration Number
- NCT02620020
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 880
- Registration Number
- NCT02612454
- Locations
- 🇬🇧
Regeneron Investigational Site, Sheffield, South Yorkshire, United Kingdom
🇩🇪Regeneron Study Site, Muenchen, Germany
🇺🇸Regeneron Investigational site, Philadelphia, Pennsylvania, United States